LABORATORIO REIG JOFRE (FEQ1) AI Stock Analysis

LABORATORIO REIG JOFRE

(Frankfurt:FEQ1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Business model diversificationA dual revenue model (branded/specialty medicines plus CDMO services) provides structural balance: product sales drive margin upside while contract manufacturing supplies recurring fee-based revenue and capacity utilization, reducing single-source demand risk and supporting steady cash flow over cycles.

Negative Factors

Sharp 2025 revenue & margin hitA large year-on-year revenue decline and collapse in operating margins materially undermine sustainable earnings power. Such deterioration reduces retained earnings available for reinvestment and makes achieving prior returns difficult without clear signs of demand recovery or cost restructuring.

LABORATORIO REIG JOFRE (FEQ1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 212.43M
Dividend Yield: 0.75%
Average Volume (3M): ―
Price to Earnings (P/E): 30.5
Beta (1Y): 0.34
Revenue Growth: -0.42%
EPS Growth: 4.56%
Country: Germany
Employees: 1,512
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs,...

LABORATORIO REIG JOFRE Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:FEQ1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:CBAV	85Outperform	EUR 867.34M	19.00	41.91%	2.95%	10.89%	17.12%
ES:ROVI	78Outperform	EUR 3.16B	17.28	27.84%	1.53%	3.21%	39.34%
ES:GRF	68Neutral	EUR 6.52B	16.38	8.43%	0.75%	-0.33%	51.93%
ES:ALM	65Neutral	EUR 2.31B	32.00	4.78%	1.74%	9.67%	174.00%
ES:FAE	61Neutral	EUR 1.50B	11.10	18.19%	2.65%	31.88%	-20.09%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

DE:FEQ1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:FEQ1	LABORATORIO REIG JOFRE	2.53	-0.31	-10.88%
ES:ALM	Almirall SA	10.60	-1.34	-11.24%
ES:CBAV	Clinica Baviera	53.20	12.09	29.42%
ES:FAE	Faes Farma	4.83	0.50	11.59%
ES:GRF	Grifols (0RDU)	10.97	-0.17	-1.53%
ES:ROVI	Laboratorios Farmaceuticos Rovi	62.55	3.88	6.61%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

LABORATORIO REIG JOFRE AI Stock Analysis